Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News FibroGen Inc FGEN

Healthcare Biotechnology
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor ... see more

Recent & Breaking News (NDAQ:FGEN)

FGEN FINAL DEADLINE FRIDAY: ROSEN, A LEADING LAW FIRM, Encourages FibroGen, Inc. Investors with Losses to Secure Counsel Before Important June 11 Deadline in Securities Class Action - FGEN

PR Newswire June 9, 2021

FINAL DEADLINE IMMINENT: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

ACCESSWIRE IA June 9, 2021

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against FibroGen Inc. (FGEN)

Business Wire June 9, 2021

FGEN Upcoming Deadline: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

ACCESSWIRE IA June 9, 2021

FRIDAY DEADLINE NOTICE: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Newsfile June 9, 2021

FINAL DEADLINE FRIDAY: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $750,000 to Contact the Firm

ACCESSWIRE IA June 9, 2021

FIBROGEN 72 HOUR DEADLINE ALERT: Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors With Losses in Excess of $100,000 of Deadline in Class Action Lawsuits Against FibroGen, Inc. - FGEN

Business Wire June 8, 2021

FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of FGEN, PTON and UI

GlobeNewswire June 8, 2021

FibroGen Shareholder Alert

Newsfile June 8, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in FibroGen, Inc. of Class Action Lawsuit and Upcoming Deadline - FGEN

GlobeNewswire June 8, 2021

3-Day Deadline Alert: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $750,000 to Contact the Firm

ACCESSWIRE IA June 8, 2021

Lead Plaintiff Deadline Approaching: Kessler Topaz Meltzer & Check, LLP Announces Deadline in Securities Fraud Class Action Lawsuit Filed Against FibroGen, Inc.

GlobeNewswire June 8, 2021

FGEN LAWSUIT: The Law Offices of Vincent Wong Notify Investors of a Class Action Lawsuit Involving FibroGen, Inc.

Newsfile June 8, 2021

FGEN Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds FibroGen, Inc. Investors of Class Action and Encourages Investors to Contact the Firm

Business Wire June 8, 2021

FRIDAY DEADLINE REMINDER: The Schall Law Firm Files Securities Class Action Suit with Extended Class Period Against FibroGen, Inc. and Encourages Investors with Losses in Excess of $250,000 to Contact the Firm

Newsfile June 8, 2021

FIBROGEN INVESTORS: June 11, 2021 Filing Deadline in Class Action - Contact Lieff Cabraser

ACCESSWIRE IA June 8, 2021

JUNE 11 2021 FGEN INVESTOR FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Fibrogen Inc.

Newsfile June 8, 2021

SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KSF REMINDS DOX, FGEN, PTON, UI INVESTORS of Lead Plaintiff Deadline in Class Action Lawsuits

GlobeNewswire June 7, 2021

FGEN ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of June 11, 2021 in the Class Action Filed on Behalf of FibroGen, Inc. Limited Shareholders

Newsfile June 7, 2021

FibroGen Deadline Alert

Newsfile June 7, 2021